Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full ...
I revved up my longevity protocols and sought out the latest predictive screenings. Was I seizing control of my health or ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven ...
More than 10,000 Americans who suffer from chronic liver disease are on a waitlist for a liver transplant, but there are not ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 1:10 PM ESTCompany ParticipantsMichael Morrissey - CEO, President ...
In decompensated alcohol-related cirrhosis, sustained alcohol abstinence is highly associated with liver recompensation, improved function, and more.
The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results